About Skites Pharma Private Limited
Data last updated:
Skites Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 16 March 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24304MH2017PTC292537. Its GSTIN is 27AAYCS3442F1ZY (Maharashtra).
The company has an authorised share capital of ₹7 Cr and a paid-up capital of ₹5.94 Cr. It is led by directors including Mahesh Kantilal Shah and Samir Jayantilal Shah.
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Flr – G 15 Mehta Mahal P L Khandke Marg Mathew Road Opera House Girgaon, Mumbai, Maharashtra, India – 400004.
As per the financials filed for FY 2025, the company reported a revenue of ₹661.04 Cr, a decline of 17% compared to the previous year. For the same year it recorded a net loss of ₹11.94 Cr (net margin -1.8%) and EBITDA of ₹22.26 Lakh (EBITDA margin 0%). Revenue has grown at a compounded annual rate (CAGR) of 6% over three years and 18% over five years.
The company has about 459 employees on its provident fund (EPFO) records. Its group structure includes 4 subsidiaries.
The company is associated with 1 brand: Skites Pharma. As per MCA filings, the company has open charges of ₹79.92 Cr on record. Court records list 21 cases involving the company, including 18 filed by the company and 3 filed against it; 13 cases are pending. The company has 3 deals on record (1 rights issue, 1 funding round, 1 secondary share transfer), with disclosed funding of ₹60 Cr; the latest was in March 2021. Its 9 peer companies in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 4 larger and 5 smaller; the largest is Takeda Biopharmaceuticals India Private Limited with revenue of ₹726.51 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website skitespharma.com.
Company details
Contact details
Skites Pharma Private Limited's registered office is in Mumbai, Maharashtra. Its website is skitespharma.com. Its e-mail address is in the company report.
- Email
- Website
- Social Media
- Registered AddressFlr – G 15 Mehta Mahal P L Khandke Marg Mathew Road Opera House Girgaon, Mumbai, Maharashtra, India – 400004
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Skites Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Skites Pharma operates one associated brand: Skites Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Distributes pharmaceuticals through trade, B2B, hospital supplies, and direct delivery. | skitespharma.com |
Business activity
The main business activity of Skites Pharma is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Skites Pharma Private Limited, buy the company report.
Financials of Skites Pharma Private Limited
FY 2025 filings availableSkites Pharma Private Limited reported revenue of ₹661.04 Cr (down 17% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 17% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 18%. EBITDA fell 93% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹22.26 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹11.94 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 0% | ||||
| Net Profit Margin | -1.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Skites Pharma Private Limited, buy the company report.
Board of directors of Skites Pharma Private Limited
Skites Pharma has 4 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mahesh Kantilal Shah Also directs: Shroff Pharma LLP, S Kant India Private Limited, Ashok GNXT Pharma Private Limited and 1 more | Director | 13 Feb 2018 | 8 Years 8 Months | Current |
| Samir Jayantilal Shah | Director | 16 Mar 2017 | 9 Years 7 Months | Current |
| Rohan Mahesh Shah | Director | 16 Mar 2017 | 9 Years 7 Months | Current |
| Yusuke Kumaki Also directs: S Kant India Private Limited, Ashok GNXT Pharma Private Limited | Director | 27 Jun 2025 | 1 Years 4 Months | Current |
Peer comparison
Skites Pharma Private Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Takeda Biopharmaceuticals India Private Limited | ₹726.51 Cr (FY 2025) | -7.0% | Gurgaon, Haryana, India | |||
| Pfizer Products India Private Limited | ₹723.76 Cr (FY 2025) | 18.0% | Mumbai, Maharashtra, India | |||
| Vasu Agencies Drugs Private Limited | ₹682.72 Cr (FY 2025) | 15.0% | Hyderabad, Telangana, India | |||
| Glaxosmithkline Consumer Private Limited | ₹675.32 Cr (FY 2025) | 13.0% | Patiala, Punjab, India | |||
| Skites Pharma Private Limitedthis company | ₹661.04 Cr (FY 2025) | -₹11.94 Cr | -1.8% | -17.0% | 459 | Mumbai, Maharashtra, India |
| Dhruvi Healthcare Private Limited | ₹634.47 Cr (FY 2025) | 22.0% | Ahmedabad, Gujarat, India | |||
| Remus Pharmaceuticals Limited | ₹625.34 Cr (FY 2025) | 190.0% | Ahmedabad, Gujarat, India | |||
| Vardhman Health Specialities Private Limited | ₹624.18 Cr (FY 2025) | 9.0% | Bangalore, Karnataka, India | |||
| Bayer Zydus Pharma Private Limited | ₹619.33 Cr (FY 2025) | 23.0% | Thane, Maharashtra, India | |||
| Auro Enterprises(India)Private Limited | ₹616.87 Cr (FY 2025) | 2724.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Skites Pharma Private Limited, buy the company report.
Auditor
Skites Pharma Private Limited is audited by C N K & ASSOCIATES LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| C N K & ASSOCIATES LLP | FY 2023 | 101961W/W100036 |
Shareholding
The shareholding of Skites Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Skites Pharma Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 22 Jun 2018 | 100194077 | Hdfc Bank Limited | ₹79.92 Cr | Open |
To see the full charge records of Skites Pharma Private Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Skites Pharma Private Limited has 3 deals on record (1 rights issue, 1 funding round, 1 secondary share transfer), with disclosed funding of ₹60 Cr; the latest was in March 2021.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2021 | Funding round | ₹60 Cr | Investors: Toyota Tsusho Corporation |
| Oct 2019 | Rights issue | ₹4.74 Cr | Investors: 4 individuals |
| Mar 2018 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: 2 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Skites Pharma Private Limited has 21 court cases on record: 18 filed by Skites Pharma, 3 filed against it. 13 cases are pending and 8 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 17 | 2 | 11 |
| High courts | 4 | 1 | 2 |
Cases on record (5 of 21)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai City Civil Court, Maharashtra | Commercial suit | Filed by the company against M/S 3S Healthcare Pvt Ltd., | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (SUMMONS CASES SS) | Filed by the company against Croissance Biomed Pvt Ltd and 3 others | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Ss cases s) | Filed by the company against M/S. Rapturous Retails Innovation Private Limited and 1 other | Pending |
| District court, Mumbai City Civil Court, Maharashtra | Interim or miscellaneous application | Filed by the company against M/S 3S Healthcare Pvt Ltd., | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Commercial matter | Filed by the company against M/S. Rapturous Retails Innovation Private Limited | Disposed |
To see the full case history of Skites Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Skites Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Skites Pharma has 4 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Shroff Pharma LLP | AAC-6816 | |
| S Kant India Private Limited | U24290MH2023PTC397388 | |
| Ashok GNXT Pharma Private Limited | U51909GJ2019PTC107421 | |
| Skites Retail Private Limited | U52399MH2021PTC354483 |
To see the full group structure of Skites Pharma Private Limited, buy the company report.
Employees & EPFO
Skites Pharma Private Limited has a workforce of 459 employees on its EPFO records as of Apr 03, 2024, across 1 active EPFO establishment.
GST
Skites Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAYCS3442F1ZY | Maharashtra | Active | 15 Jul 2017 |
To see the full GST registrations and return filing status of Skites Pharma Private Limited, buy the company report.
Recent activity
Skites Pharma Private Limited has 8 board changes on record since 2017: 6 appointments and 2 cessations. The latest: Eishi Takahide Maekawa ceased to be Director on 27 Jun 2025.
1 earlier event is in the company report.
Frequently asked questions
Skites Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 16 March 2017 (9+ years old) and is registered under CIN U24304MH2017PTC292537.
Skites Pharma has 4 current directors:
- Mahesh Kantilal Shah - Director
- Samir Jayantilal Shah - Director
- Rohan Mahesh Shah - Director
- Yusuke Kumaki - Director
The latest financial statements of Skites Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 25 September 2025. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Skites Pharma is 27AAYCS3442F1ZY, registered in Maharashtra.
The CIN (Corporate Identification Number) of Skites Pharma is U24304MH2017PTC292537. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Skites Pharma has 21 court cases on record: 18 filed by the company and 3 filed against it. 13 are pending. Most are in the district courts.
Skites Pharma was incorporated on 16 March 2017, making it 9+ years old. It is registered with the Registrar of Companies, Mumbai.
Skites Pharma has 3 deals on record (1 rights issue, 1 funding round, 1 secondary share transfer), with disclosed funding of ₹60 Cr; the latest was in March 2021.
The peers of Skites Pharma by revenue are Takeda Biopharmaceuticals India Private Limited, Pfizer Products India Private Limited, Vasu Agencies Drugs Private Limited, Glaxosmithkline Consumer Private Limited, Dhruvi Healthcare Private Limited and 4 more, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Eishi Takahide Maekawa ceased to be Director on 27 Jun 2025. Yusuke Kumaki was appointed as Director on 27 Jun 2025. Eishi Takahide Maekawa was appointed as Director on 16 Jul 2021. Skites Pharma has 8 board changes on record in total.
Skites Pharma can be reached through the website skitespharma.com. Its registered office is in Mumbai, Maharashtra, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
